Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
OmniAb
OABI
OmniAb
Regulatory Pressures And Competition Will Limit Prospects But Trigger Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
10 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$3.00
33.0% undervalued
intrinsic discount
16 Aug
US$2.01
Loading
1Y
-51.9%
7D
2.0%
Author's Valuation
US$3.0
33.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$3.0
33.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-64m
66m
2019
2021
2023
2025
2027
2028
Revenue US$34.0m
Earnings US$4.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
31.26%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.31%
Calculation
US$4.35m
Earnings '28
x
116.82x
PE Ratio '28
=
US$507.84m
Market Cap '28
US$507.84m
Market Cap '28
/
137.39m
No. shares '28
=
US$3.70
Share Price '28
US$3.70
Share Price '28
Discounted to 2025 @ 7.31% p.a.
=
US$2.99
Fair Value '25
